Core Viewpoint - The company acknowledges the increasing interest from foreign patients in seeking medical treatment in China due to lower costs and higher efficiency, particularly after the implementation of the 244-hour visa-free policy [1]. Group 1: Company Plans and Strategies - The company has established international medical departments or special departments in hospitals located in major cities to provide services that meet international standards [1]. - The company plans to leverage its brand scale and international network to continuously optimize the treatment process and enhance the convenience of medical visits [1]. - The company aims to expand the influence of its international medical department to attract more foreign patients [1]. Group 2: Market Trends and Growth - There is a noticeable trend of increasing foreign patients coming to China for medical treatment, which the company intends to capitalize on [1]. - The company did not provide specific growth rates for foreign patients or revenue increases compared to domestic figures in its response [1].

Group 1 - The core viewpoint of the articles highlights He Eye Hospital's recent membership in the National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance, which aims to enhance clinical applications of AI in healthcare and improve diagnostic capabilities [1] - He Eye Hospital plans to leverage the alliance's resources to deepen international cooperation in research and development, focusing on the application of AI in screening various eye diseases [1] - The establishment of the AI sub-alliance on January 4, 2025, has already attracted over 100 member units, promoting the integration of high-quality medical resources into grassroots healthcare services [1] Group 2 - He Eye Hospital is positioned as a digital eye health ecosystem group, aiming to create a "Smart Bright City" by collaborating with institutions like Liaoning He Medical College and He Eye Industry Group [2] - The company is focusing on eye health, anti-aging, and longevity technologies, integrating big data, AI, and genetic technologies to develop a new model for comprehensive eye health and chronic disease management [2] - In terms of intelligent applications, He Eye Hospital has developed an intelligent diagnostic system and a specialized imaging cloud platform, utilizing deep learning algorithms for health management [2] Group 3 - He Eye Hospital is also working to promote China's eye care technologies and experiences internationally, through talent training and technology sharing, aiming to enhance local eye health service capabilities in other countries [3] - The company seeks to provide replicable and sustainable models for smart eye health ecosystems, based on innovative screening technologies and management practices [3]

Group 1 - The company, Chaoju Eye Care (02219), announced a share buyback plan [1] - The company will spend HKD 159,000 to repurchase 60,000 shares [1]

Core Insights - He Eye Hospital has officially become a member of the National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance, enhancing its integration into a national-level innovative platform for smart healthcare and AI clinical applications [1][2] - The National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance was established on January 4, 2025, with over 100 member units currently [1] - He Eye Hospital aims to create a "Smart Light City" by collaborating with various institutions, focusing on eye health, anti-aging, and longevity technology, utilizing new technologies such as big data, AI, and stem cells [1][2] Industry Developments - In the field of ophthalmic intelligent applications, He Eye Hospital has developed an intelligent auxiliary diagnostic system and an ophthalmic specialty imaging cloud platform, leveraging deep learning algorithms for health management [2] - The "He Diabetes Manager" integrates dynamic blood glucose monitoring to provide personalized health management solutions for diabetes patients, ensuring precise blood sugar control and eye disease prevention throughout their life cycle [2] - The "Bright House" initiative utilizes smart ophthalmic equipment to screen for eye diseases and related chronic conditions, creating a digitally empowered grassroots eye health management scenario [2] International Collaboration - He Eye Hospital is actively responding to the Belt and Road Initiative by collaborating with partners to promote China's eye care technology and experience internationally [2] - The hospital aims to enhance local grassroots eye health service capabilities in Belt and Road countries through talent training, technology sharing, and the establishment of blindness prevention models [2] - The membership in the National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance will facilitate deeper international cooperation in research and development, expanding AI applications in ophthalmic disease screening [2]

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Group 1 - The core viewpoint of the news is that He Eye Hospital has officially become a member of the National Ophthalmology Alliance Artificial Intelligence Sub-Alliance, enhancing its integration into a national-level innovative platform for smart healthcare and AI clinical applications [1] - The National Ophthalmology Alliance Artificial Intelligence Sub-Alliance was established on January 4, 2025, with over 100 member units, aiming to promote the development of AI technology in ophthalmology and improve access to quality eye health services [1] - He Eye Hospital aims to build a "Smart Bright City" by collaborating with various institutions, focusing on eye health, anti-aging, and longevity technology, integrating new technologies such as big data, AI, and stem cells [1] Group 2 - He Eye Hospital has developed an intelligent auxiliary diagnosis system and an ophthalmology specialty intelligent imaging cloud platform, utilizing deep learning algorithms for health management [2] - The "He Diabetes Manager" combines dynamic blood glucose monitoring to achieve precise blood sugar control and eye disease prevention for diabetes patients throughout their life cycle [2] - He Eye Hospital is actively responding to the Belt and Road Initiative by promoting Chinese ophthalmic blindness prevention technology and experience internationally, enhancing local eye health service capabilities in partner countries [2] Group 3 - He Eye Hospital plans to leverage its membership in the National Ophthalmology Alliance Artificial Intelligence Sub-Alliance to deepen international cooperation in research and application of AI in ophthalmology, contributing to the health of the broader community [3]

Group 1 - The company, Guangzheng Eye Hospital, will disclose the number of shareholders in its periodic reports according to the regulations of the CSRC and Shenzhen Stock Exchange [1] - Investors can send valid shareholding proof documents to the company's email for identity verification, after which the company will respond [1]

Core Insights - The article highlights the official certification of Nanjing Aier Eye Hospital as the first clinical application cooperation center for the EVO+ ICL (V5) technology, marking a significant milestone in refractive surgery in the region [1][3] - The EVO+ ICL (V5) technology is recognized for its advancements in optimizing night vision, providing patients in Jiangsu with access to cutting-edge refractive correction solutions [1][5] Group 1: Certification and Achievements - Nanjing Aier Eye Hospital received the "EVO+ ICL (V5) First Clinical Application Cooperation Center" certification and the "EVO+ ICL (V5) Certified Surgeon" certificate for its director, Xiong Juan, indicating a strong clinical capability [1][3] - The hospital's achievement reflects the strategic empowerment of the Aier Eye Group and the regional technical strength, showcasing a complete cycle from group leadership to hospital implementation [3] Group 2: Technological Advancements - The EVO+ ICL (V5) lens features a significant technological upgrade with an optical zone expanded to 6.1mm, effectively addressing night vision issues such as glare and halos for myopic patients [5] - The V5 lens allows for customized correction precision for moderate to low myopia, enhancing visual quality for patients with specific needs [5] Group 3: Clinical Practice and Expertise - Nanjing Aier Eye Hospital successfully performed Jiangsu's first EVO+ ICL (V5) implantation surgery on January 4, utilizing advanced technology such as the Zeiss ARTEVO 800 digital navigation 3D microscope for enhanced surgical precision [8] - Xiong Juan, the certified surgeon, is a leading figure in the refractive surgery department, with extensive international certifications and experience in performing thousands of refractive surgeries [9] Group 4: Community Impact and Future Plans - The dual certification is seen as a starting point for high-quality service, aiming to provide Jiangsu patients with faster and safer access to innovative refractive correction technologies [12] - Nanjing Aier Eye Hospital plans to leverage its global ophthalmic resources and local surgical platform to offer expert consultations and educational outreach, ensuring that patients with high myopia and astigmatism receive precise and safe corrective services [12][15]

Core Viewpoint - The establishment of the Traditional Chinese Medicine (TCM) Eye Clinic at Qingdao Huaxia Eye Hospital marks a significant step towards the deep integration of traditional and modern medicine, providing a more diverse, systematic, and personalized health pathway for eye disease patients [1][3]. Group 1: Hospital's Strategic Initiatives - The hospital is responding to the national call for the collaborative development of TCM and Western medicine by establishing the TCM Eye Clinic, which enhances its service offerings and meets the public's demand for integrated healthcare [3]. - The establishment of the TCM Eye Clinic is seen as a new starting point for high-quality service, with plans for clinical, research, and talent development to create a comprehensive eye health service model that integrates prevention, treatment, and rehabilitation [5]. Group 2: Leadership and Expertise - Dr. Li Qing has been appointed as the head of the TCM Eye Clinic, bringing extensive clinical experience and recognition in TCM ophthalmology, which strengthens the professional foundation and confidence in this emerging discipline [7]. Group 3: Service Offerings - The TCM Eye Clinic will focus on three main areas: 1. Providing TCM therapies for common issues such as dry eye, visual fatigue, and myopia prevention [9]. 2. Offering collaborative interventions for chronic eye diseases like age-related macular degeneration and diabetic retinopathy, combining TCM with standard Western treatments to improve symptoms and quality of life [9]. 3. Promoting eye disease prevention and health management through TCM principles, including health education and body constitution identification [9]. Group 4: Future Outlook - The hospital aims to leverage the establishment of the TCM Eye Clinic to explore innovative paths for integrating TCM and Western medicine in eye health, continuously enhancing diagnostic and service quality for the local community [11].

截至2026年1月12日收盘，何氏眼科(301103)报收于20.84元，上涨2.86%，换手率1.99%，成交量3.14万 手，成交额6458.06万元。 董秘最新回复 投资者： 请问何星儒何总，贵公司股价长期处于低位，对公司品牌带来极大负面影响，为何不积极回 购股份提升公司的市场价值呢？ 董秘： 尊敬的投资者您好，截止目前公司已累计回购股份2,722,719股。关于股份回购计划，公司管理 层将根据公司资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划， 将严格按照法律法规及交易所规则，履行决策程序并及时披露相关信息。公司将继续做好经营管理，夯 实企业内在价值，坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场 品牌建设，努力为投资者创造长期价值。谢谢！ 投资者： 董秘你好，公司长期大幅破发，投资者毫无获得感，作为辽宁地区知名企业，后续公司有什 么具体的稳定提升股价的措施吗？ 董秘： 尊敬的投资者您好，股价的波动受市场整体情绪、行业板块轮动、资金偏好等多重因素综合影 响。公司坚持聚焦主业，稳健经营，以投资者为本，通过不断完善公司治理，积极加强与国内外同领域 ...